1. Ambarella Inc (AMBA)
Ambarella is a leading developer of low-power, high-definition video compression and image processing semiconductors. Their products are used in high definition (HD) cameras including security IP-cameras, wearable sports cameras, digital still cameras, and automotive video recorders. Ambarella technology is also used in television broadcasting infrastructure systems. The advancements in display technology have caused a tremendous growth in video content worldwide, estimated to have an average CAGR of 90% for 2011-2016. Their main competitive strength is high performance and low power and storage requirements, 75% of their workforce is in R&D. The company has a net cash position of 120 million, I have estimated their forward P/E at 15 with a growth rate near 20%. Financials and Fundamentals
Ambarella is a leading developer of low-power, high-definition video compression and image processing semiconductors. Their products are used in high definition (HD) cameras including security IP-cameras, wearable sports cameras, digital still cameras, and automotive video recorders. Ambarella technology is also used in television broadcasting infrastructure systems. The advancements in display technology have caused a tremendous growth in video content worldwide, estimated to have an average CAGR of 90% for 2011-2016. Their main competitive strength is high performance and low power and storage requirements, 75% of their workforce is in R&D. The company has a net cash position of 120 million, I have estimated their forward P/E at 15 with a growth rate near 20%. Financials and Fundamentals
2. Celgene (CELG)
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. It's flagship drugs are Thalomid, Revlimid, Abraxane, Vidaza. Celgene is a leader in it's field, with many more products on the way. The company announced Q3 results recently, beating analyst estimates on revenue but coming short of EPS expectations and slightly increasing their yearly outlook. Insiders have been heavy buyers of the stock in the past 2 years. Financials and Fundamentals
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. It's flagship drugs are Thalomid, Revlimid, Abraxane, Vidaza. Celgene is a leader in it's field, with many more products on the way. The company announced Q3 results recently, beating analyst estimates on revenue but coming short of EPS expectations and slightly increasing their yearly outlook. Insiders have been heavy buyers of the stock in the past 2 years. Financials and Fundamentals
3. Interactive Intelligence (ININ)
Interactive Intelligence Group, Inc. provides contact center and business communications solutions. It offers Interactive Intelligence Customer Interaction Center (CIC), a solution for voice, data, and process automation. The company provides its solutions for use in teleservices, insurance, banking, accounts receivable management, utilities, healthcare, retail, technology, government, and business services industries in the Americas, Europe, the Middle East and Africa, and the Asia-Pacific. They are widely recognized as a leader in contact center solutions. See below for my previous article written on ININ. Financials and Fundamentals
Interactive Intelligence Group, Inc. provides contact center and business communications solutions. It offers Interactive Intelligence Customer Interaction Center (CIC), a solution for voice, data, and process automation. The company provides its solutions for use in teleservices, insurance, banking, accounts receivable management, utilities, healthcare, retail, technology, government, and business services industries in the Americas, Europe, the Middle East and Africa, and the Asia-Pacific. They are widely recognized as a leader in contact center solutions. See below for my previous article written on ININ. Financials and Fundamentals
4. Michael Kors Holdings Ltd (KORS)
Michael Kors Holdings Limited engages in the design, marketing, distribution, and retailing of branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing. As of March 30, 2013, it had 231 retail stores, including concessions in North America; and 73 international retail stores, including concessions in Europe and Japan. The company reported a 49 per cent jump in net income in Q£, beating Wall Street forecasts. Also, It now expects earning per share of $2.77 to $2.81 on revenue of $2.9bn to $3bn. It had previously raised its guidance in August, then expecting per-share earnings of $2.67 to $2.69 on comparable revenue. The brand has gained incredible momentum in the past couple of years, outgrowing many of it's rivals. There is still considerable potential, given that North America represents nearly 80% of sales, while they are gaining foothold in Asia and Europe, world's premier luxury goods markets. Despite it's high valuation, I still see a big profit potential in the stock, and I am not alone. Top investors like Mario Gabelli, Steve Mandel and Andreas Halvorsen hold it too. Financials and Fundamentals
Michael Kors Holdings Limited engages in the design, marketing, distribution, and retailing of branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing. As of March 30, 2013, it had 231 retail stores, including concessions in North America; and 73 international retail stores, including concessions in Europe and Japan. The company reported a 49 per cent jump in net income in Q£, beating Wall Street forecasts. Also, It now expects earning per share of $2.77 to $2.81 on revenue of $2.9bn to $3bn. It had previously raised its guidance in August, then expecting per-share earnings of $2.67 to $2.69 on comparable revenue. The brand has gained incredible momentum in the past couple of years, outgrowing many of it's rivals. There is still considerable potential, given that North America represents nearly 80% of sales, while they are gaining foothold in Asia and Europe, world's premier luxury goods markets. Despite it's high valuation, I still see a big profit potential in the stock, and I am not alone. Top investors like Mario Gabelli, Steve Mandel and Andreas Halvorsen hold it too. Financials and Fundamentals
5. Maximus Inc (MMS)
MAXIMUS, Inc. provides business process services to various government health and human services agencies in the United States, Australia, Canada, Saudi Arabia, and the United Kingdom. It's expertise lies in administering government-sponsored programs, such as Medicaid, the Children’s Health Insurance Program (CHIP), health care reform, welfare-to-work, Medicare, child support enforcement, and other government programs. The company is a leading administrator of Medicaid and CHIP services in the United States, the premier provider of workforce-centered services in the United States, Australia, the United Kingdom and Saudi Arabia. A pioneer of welfare reform, placing approximately 500,000 individuals into unsubsidized employment. Their main markets are exactly countries, which will in my opinion undergo significant budget restructurings and social program reforms. Maximus is in the perfect spot to profit from these trends.
Financials and Fundamentals
MAXIMUS, Inc. provides business process services to various government health and human services agencies in the United States, Australia, Canada, Saudi Arabia, and the United Kingdom. It's expertise lies in administering government-sponsored programs, such as Medicaid, the Children’s Health Insurance Program (CHIP), health care reform, welfare-to-work, Medicare, child support enforcement, and other government programs. The company is a leading administrator of Medicaid and CHIP services in the United States, the premier provider of workforce-centered services in the United States, Australia, the United Kingdom and Saudi Arabia. A pioneer of welfare reform, placing approximately 500,000 individuals into unsubsidized employment. Their main markets are exactly countries, which will in my opinion undergo significant budget restructurings and social program reforms. Maximus is in the perfect spot to profit from these trends.
Financials and Fundamentals
6. Ulta Salon Cosmetics and Fragrance Inc
The company operates specialty retail stores in the United States. Its stores offer over 20 000 3rd party as well as private branded cosmetics, fragrance, haircare, and skincare products, as well as related accessories and services.
As of August 3, 2013 the Company operates 609 retail stores across 46 states and also distributes its products through their web. The competitive strength is apparent, it is the largest cosmetic chain in the US, offering the most comprehensive service to it's customers. Cosmetics is a high margin and stable business, and they have clearly a dominant position. Their latest results showed 25% sales growth, increased gross margins to 35.3% and it's loyalty program expanding at a 19% to a record 12 million members. Financials and Fundamentals
The company operates specialty retail stores in the United States. Its stores offer over 20 000 3rd party as well as private branded cosmetics, fragrance, haircare, and skincare products, as well as related accessories and services.
As of August 3, 2013 the Company operates 609 retail stores across 46 states and also distributes its products through their web. The competitive strength is apparent, it is the largest cosmetic chain in the US, offering the most comprehensive service to it's customers. Cosmetics is a high margin and stable business, and they have clearly a dominant position. Their latest results showed 25% sales growth, increased gross margins to 35.3% and it's loyalty program expanding at a 19% to a record 12 million members. Financials and Fundamentals
7. United Therapeutics Corporation (UTHR)United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of drugs fighting cardiovascular, infectious diseases and cancer. The lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to Remodulin, the company has 8 products in it's pipeline in various stages of trials. There are very low expectations regarding their future, the stock is trading at a forward P/E of only 13. Yet my analysis indicates, they will be able to grow at least 15-20% in the near future, as was demonstrated in their last quarterly results. The biggest surprise was the growth for drug Tyvaso, which reached sales of 120 million USD (up 36% YoY). High growth/Low P/E stocks are very rare, the markets seem to underappreciate this company and it's management. I believe they will continue to grow at this pace in the future, once wall street recognizes that, both it's price and earnings multiples will expand at a rapid pace.
RSS Feed